Aravive to Host Virtual Expert Event Focused on Ovarian and Renal Cancer on November 20, 2020

Rhea-AI Summary

Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company, will host a virtual event on November 20, 2020, focused on Ovarian and Renal Cancer. The event will showcase clinical development plans for AVB-500, targeting platinum-resistant ovarian cancer and clear cell renal cell carcinoma. Leading oncologists, including Katherine Fuh and Eric Jonasch, will provide insights on treatment advancements. A live webcast will be accessible on the Aravive website, with a replay available post-event. Aravive's AVB-500 has shown promising results in recent trials, with all patients in the 15 mg/kg cohort experiencing clinical benefits.

HOUSTON, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced the Company will host a virtual Ovarian and Renal Cancer Expert Event on Friday, November 20, 2020 from 9:00 a.m. to 10:30 a.m. ET.

Aravive will review its clinical development plans for AVB-500 in platinum resistant ovarian cancer and clear cell renal cell carcinoma. The program will also feature perspectives on the evolving treatment landscape in gynecologic cancers and renal cancer from the following leading oncologists.

• Katherine Fuh, M.D., Ph.D., Gynecologic Oncologist & Assistant Professor, Division of Gynecologic Oncology, Washington University
  
  
• Eric Jonasch, M.D., Director, VHL Clinical Center & Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
  

A live webcast of the event can be accessed in the Investors section of the Aravive website at https://ir.aravive.com/events-and-presentations. The webcast replay will be archived on the Company’s website following the live event.

About Aravive
Aravive, Inc. is a clinical-stage oncology company developing transformative therapeutics designed to halt the progression of life-threatening diseases. Aravive’s lead therapeutic, AVB-500, is an ultra-high affinity decoy protein that targets the GAS6-AXL signaling pathway associated with tumor cell growth. Aravive recently successfully completed a Phase 1b trial of AVB-500 in platinum resistant ovarian cancer and selected 15 mg/kg as the dose for the pivotal trial. While the Phase 1b trial of AVB-500 in platinum resistant ovarian cancer was a safety trial and not powered to demonstrate efficacy, all 5 patients in the 15 mg/kg cohort experienced clinical benefit, with 1 complete response, 2 partial responses, and 2 stable disease. The Company also intends to initiate a Phase 1b/Phase 2 trial of AVB-500 in clear cell renal cell carcinoma later this year. For more information, please visit www.aravive.com.

Contacts:
Media:
Sheryl Seapy, W2O
sseapy@w2ogroup.com
(213) 262-9390

Investors:
Luke Heagle, W2O
lheagle@w2ogroup.com
(910) 726-1372

FAQ

What is the date of Aravive's virtual cancer expert event?

Aravive's virtual Ovarian and Renal Cancer Expert Event is scheduled for November 20, 2020.

What is AVB-500 and its significance?

AVB-500 is Aravive's lead therapeutic targeting the GAS6-AXL pathway, showing promise in treating platinum-resistant ovarian cancer.

Who are the featured oncologists at the Aravive event?

The event will feature Dr. Katherine Fuh and Dr. Eric Jonasch, both experts in gynecologic and renal oncology.

How can I access the webcast of Aravive's event?

The live webcast can be accessed from the Investors section on Aravive's website.

What were the results of the Phase 1b trial of AVB-500?

All 5 patients in the 15 mg/kg cohort of the trial experienced clinical benefits, including 1 complete response and 2 partial responses.